Athenex Inc (NASDAQ:ATNX) Director Sheldon Trainor-Degirolamo sold 12,401 shares of the firm’s stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $16.81, for a total value of $208,460.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Sheldon Trainor-Degirolamo also recently made the following trade(s):

  • On Monday, June 4th, Sheldon Trainor-Degirolamo sold 31,633 shares of Athenex stock. The stock was sold at an average price of $16.81, for a total value of $531,750.73.
  • On Wednesday, May 23rd, Sheldon Trainor-Degirolamo sold 121,688 shares of Athenex stock. The stock was sold at an average price of $17.01, for a total value of $2,069,912.88.

Shares of Athenex stock traded up $0.41 during trading hours on Thursday, reaching $17.91. The stock had a trading volume of 417,900 shares, compared to its average volume of 306,542. The company has a market cap of $1.06 billion and a price-to-earnings ratio of -7.72. Athenex Inc has a 1 year low of $12.30 and a 1 year high of $20.79.

Athenex (NASDAQ:ATNX) last released its quarterly earnings data on Monday, May 14th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). The firm had revenue of $37.84 million during the quarter. Athenex had a negative return on equity of 75.45% and a negative net margin of 136.72%. analysts expect that Athenex Inc will post -1.36 EPS for the current fiscal year.

A number of analysts have issued reports on the company. Zacks Investment Research raised Athenex from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Friday, June 8th. BidaskClub lowered Athenex from a “buy” rating to a “hold” rating in a research note on Saturday, May 26th. ValuEngine raised Athenex from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Needham & Company LLC assumed coverage on Athenex in a research note on Tuesday, March 6th. They issued a “buy” rating and a $30.00 price target on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $26.71.

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Athenex by 3,671.6% in the 1st quarter. Royal Bank of Canada now owns 60,874 shares of the company’s stock worth $1,035,000 after purchasing an additional 59,260 shares during the period. Millennium Management LLC raised its holdings in shares of Athenex by 108.8% in the 1st quarter. Millennium Management LLC now owns 133,663 shares of the company’s stock worth $2,274,000 after purchasing an additional 69,661 shares during the period. LPL Financial LLC purchased a new position in shares of Athenex in the 1st quarter worth about $315,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in shares of Athenex in the 1st quarter worth about $1,179,000. Finally, Jane Street Group LLC purchased a new position in shares of Athenex in the 1st quarter worth about $208,000. Institutional investors own 16.63% of the company’s stock.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.